ACTRN12621001357842撤回1 期
A phase II open label study to determine the ocular pharmacokinetics of oral OCX063, in patients requiring retinal reattachment surgery.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Provide written informed consent prior to any study procedures and who agree to adhere to all protocol requirements.
- •- Aged 18 years or older at the time of consent.
- •- Participants must agree to use contraception according to protocol
- •- Require pars plana vitrectomy with or without scleral buckling due to retinal detachment due to any cause.
排除标准
- •- Pregnant or breast-feeding.
- •- Have received any investigational medicinal product (IMP) within 30 days or 5 half-lives prior to dosing (4 months if the previous drug was a new chemical entity), whichever is longer.
- •- Have known or suspected contraindications to the IMP.
- •- Have undergone other ocular surgery performed within 6 months prior to screening or planned during the trial in the study eye, with the exception of uncomplicated cataract surgery which is allowed in the month prior.
- •- Have any additional eye disease in the study eye that, in the opinion of the investigator, could compromise or alter visual acuity during the course of the study (e.g. vein occlusion, uncontrolled intraocular pressure (IOP) greater than 24 mmHg on optimal medical treatment, glaucoma with visual field loss, uveitis or other ocular inflammatory or infectious disease, monocular vision, history of ischemic optic neuropathy, intraocular foreign body, sickle cell disease, or genetic disorders such as retinitis pigmentosa)
- •- Aphakia or Posterior-chamber Intraocular Lens Implantation with known ruptured capsule other than prior uncomplicated yttrium-aluminum-garnet (YAG) laser treatment.
- •- Have anterior segment or vitreous abnormalities in the study eye that would compromise adequate assessment of tissue compartments.
- •- Currently using or plan to use, during the trial, medications known to be toxic to the retina, lens or optic nerve, or cause vision loss.
- •- Wish to continue the intake of other restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
- •- Have a diagnosis of a serious or unstable systemic or eye disease and other conditions that, in the clinical judgment of the investigator, are likely to interfere with the analyses of safety and efficacy in this study. Patients with an expected life expectancy of less than 2 years are also excluded.
- •- Other than requiring retinal repair, have any other medical condition or significant co-morbidities, clinically relevant social or psychiatric conditions, or any finding during Screening, which in the investigator’s opinion may put the subject at risk or interfere with the study objectives.
研究者
相似试验
尚未招募
2 期
Treating congenital ichthyosis with targeted therapy (Secukinumab)CTRI/2022/02/040195Department of Health Research
尚未招募
不适用
A Phase II open label, umbrella study evaluating the efficacy and safety of Fulvestrant plus DNA damage repair inhibitors in hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitorNeoplasmsKCT0007776Seoul National University Hospital64
进行中（未招募）
1 期
Study to assess the safety and efficacy of the SpectraCure P18 SystemRecurrent prostate cancerMedDRA version: 21.0Level: PTClassification code: 10036911Term: Prostate cancer recurrent Class: 100000004864CTIS2022-502285-24-00SpectraCure AB (publ)66
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiaCD1d-positive relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)EUCTR2020-004583-26-ESAVA Therapeutics B.V.102
招募中
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiaRelapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)EUCTR2020-004583-26-FRAVA Therapeutics B.V.102